Suzuken schedules Kumamoto restart before November results for Suzuken stock

Published on 10/25/2026 at 02:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Production resumes October 19 after the July 28 earthquake. Suzuken stock enters November 11 results after a JPY 5.13 billion September buyback.

Corporate actions and reporting dates

Suzuken disclosed the Kumamoto restart plan on October 16, 2026, with production scheduled for October 19.
The company acquired 990,000 shares for JPY 5.13 billion during September 2026.
Suzuken's next earnings release is scheduled for November 11, 2026.

Suzuken, JP3398000004, Illustration mit AI erstellt.

Suzuken (ISIN JP3398000004) announced on October 16, 2026 that production at the Kumamoto Plant of subsidiary Sanwa Kagaku Kenkyusho was scheduled to resume on October 19. Japan IR reported that safety inspections and good manufacturing practice checks preceded the planned restart after earthquake damage.

What does the buyback add?

The capital-return program provides a second concrete marker for Suzuken stock. During September 2026, Suzuken acquired 990,000 ordinary shares for JPY 5,131,170,000, according to Japan IR. The August authorization set a ceiling of 4,000,000 shares and JPY 18.0 billion, giving the September purchases a defined program context.

Three milestones since August

On August 28, 2026, Suzuken authorized a buyback capped at 4,000,000 shares and JPY 18.0 billion. On October 1, 2026, it disclosed September purchases of 990,000 shares for JPY 5.13 billion. On October 16, 2026, the company set October 19 as the planned Kumamoto production restart, as reported by MarketScreener.

When are the next dates?

MarketScreener lists November 11, 2026 as the next earnings release for the second quarter of fiscal 2027. The current guidance period runs through March 31, 2027, so the November report will be the next quantified checkpoint for the fiscal-year outlook.

Market value and operating context

Suzuken had a market capitalization of JPY 381.8 billion as of October 23, 2026. Its Tokyo Stock Exchange listing covers pharmaceutical wholesaling, specialty pharmaceutical distribution, healthcare products and related medical services, while the Kumamoto restart marks a concrete operational step after the July earthquake.